Cargando…

Cardiology Involvement in Patients With Breast Cancer Treated With Trastuzumab

BACKGROUND: There is limited evidence regarding the impact of cardiology involvement in the care of cancer patients. OBJECTIVES: This study evaluated the impact of cardiology involvement on guideline-adherent cardiovascular monitoring and risk factor management in patients with breast cancer treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Demissei, Biniyam G., Adusumalli, Srinath, Hubbard, Rebecca A., Denduluri, Srinivas, Narayan, Vivek, Clark, Amy S., Shah, Payal, Knollman, Hayley, Getz, Kelly D., Aplenc, Richard, Carver, Joseph R., Ky, Bonnie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701353/
https://www.ncbi.nlm.nih.gov/pubmed/33263112
http://dx.doi.org/10.1016/j.jaccao.2020.04.010
_version_ 1783616477619814400
author Demissei, Biniyam G.
Adusumalli, Srinath
Hubbard, Rebecca A.
Denduluri, Srinivas
Narayan, Vivek
Clark, Amy S.
Shah, Payal
Knollman, Hayley
Getz, Kelly D.
Aplenc, Richard
Carver, Joseph R.
Ky, Bonnie
author_facet Demissei, Biniyam G.
Adusumalli, Srinath
Hubbard, Rebecca A.
Denduluri, Srinivas
Narayan, Vivek
Clark, Amy S.
Shah, Payal
Knollman, Hayley
Getz, Kelly D.
Aplenc, Richard
Carver, Joseph R.
Ky, Bonnie
author_sort Demissei, Biniyam G.
collection PubMed
description BACKGROUND: There is limited evidence regarding the impact of cardiology involvement in the care of cancer patients. OBJECTIVES: This study evaluated the impact of cardiology involvement on guideline-adherent cardiovascular monitoring and risk factor management in patients with breast cancer treated with trastuzumab. METHODS: In a single-center retrospective cohort study, electronic health records from 1,047 patients with breast cancer receiving trastuzumab between January 2009 and July 2018 were evaluated. A visit to a cardiology provider beginning from the 3 months before cancer therapy initiation until the last contact date defined cardiology involvement. Guideline-adherent monitoring, defined by echocardiography assessment within the 4 months before trastuzumab initiation and follow-up echocardiography at least every 4 months during therapy, was compared in patients with and without cardiology involvement before treatment initiation. Multivariable associations between cardiology involvement and the time-varying risk factors blood pressure and body mass index (BMI) were assessed by using generalized estimating equations. RESULTS: Cardiology involvement occurred in 293 (28%) patients. A higher proportion of patients with cardiology involvement before trastuzumab initiation had guideline-adherent monitoring (76.4% vs. 60.1%; p = 0.007). Cardiology involvement was associated with an average 1.5 mm Hg (95% CI: –2.9 to –0.1; p = 0.035) lower systolic blood pressure, which was more pronounced in those with hypertension (–2.7 mm Hg; 95% CI: –4.6 to –0.7; p = 0.007). Cardiology involvement was associated with a lower BMI in patients with baseline BMI ≥25 kg/m(2) (mean difference: –0.5 kg/m(2); 95% CI: –1.0 to –0.1; p = 0.027). CONCLUSIONS: Cardiology involvement in patients with breast cancer treated with trastuzumab is associated with greater adherence to cardiovascular monitoring and modest improvements in risk factor control.
format Online
Article
Text
id pubmed-7701353
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-77013532020-11-30 Cardiology Involvement in Patients With Breast Cancer Treated With Trastuzumab Demissei, Biniyam G. Adusumalli, Srinath Hubbard, Rebecca A. Denduluri, Srinivas Narayan, Vivek Clark, Amy S. Shah, Payal Knollman, Hayley Getz, Kelly D. Aplenc, Richard Carver, Joseph R. Ky, Bonnie JACC CardioOncol Original Research BACKGROUND: There is limited evidence regarding the impact of cardiology involvement in the care of cancer patients. OBJECTIVES: This study evaluated the impact of cardiology involvement on guideline-adherent cardiovascular monitoring and risk factor management in patients with breast cancer treated with trastuzumab. METHODS: In a single-center retrospective cohort study, electronic health records from 1,047 patients with breast cancer receiving trastuzumab between January 2009 and July 2018 were evaluated. A visit to a cardiology provider beginning from the 3 months before cancer therapy initiation until the last contact date defined cardiology involvement. Guideline-adherent monitoring, defined by echocardiography assessment within the 4 months before trastuzumab initiation and follow-up echocardiography at least every 4 months during therapy, was compared in patients with and without cardiology involvement before treatment initiation. Multivariable associations between cardiology involvement and the time-varying risk factors blood pressure and body mass index (BMI) were assessed by using generalized estimating equations. RESULTS: Cardiology involvement occurred in 293 (28%) patients. A higher proportion of patients with cardiology involvement before trastuzumab initiation had guideline-adherent monitoring (76.4% vs. 60.1%; p = 0.007). Cardiology involvement was associated with an average 1.5 mm Hg (95% CI: –2.9 to –0.1; p = 0.035) lower systolic blood pressure, which was more pronounced in those with hypertension (–2.7 mm Hg; 95% CI: –4.6 to –0.7; p = 0.007). Cardiology involvement was associated with a lower BMI in patients with baseline BMI ≥25 kg/m(2) (mean difference: –0.5 kg/m(2); 95% CI: –1.0 to –0.1; p = 0.027). CONCLUSIONS: Cardiology involvement in patients with breast cancer treated with trastuzumab is associated with greater adherence to cardiovascular monitoring and modest improvements in risk factor control. Elsevier 2020-06-16 /pmc/articles/PMC7701353/ /pubmed/33263112 http://dx.doi.org/10.1016/j.jaccao.2020.04.010 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Demissei, Biniyam G.
Adusumalli, Srinath
Hubbard, Rebecca A.
Denduluri, Srinivas
Narayan, Vivek
Clark, Amy S.
Shah, Payal
Knollman, Hayley
Getz, Kelly D.
Aplenc, Richard
Carver, Joseph R.
Ky, Bonnie
Cardiology Involvement in Patients With Breast Cancer Treated With Trastuzumab
title Cardiology Involvement in Patients With Breast Cancer Treated With Trastuzumab
title_full Cardiology Involvement in Patients With Breast Cancer Treated With Trastuzumab
title_fullStr Cardiology Involvement in Patients With Breast Cancer Treated With Trastuzumab
title_full_unstemmed Cardiology Involvement in Patients With Breast Cancer Treated With Trastuzumab
title_short Cardiology Involvement in Patients With Breast Cancer Treated With Trastuzumab
title_sort cardiology involvement in patients with breast cancer treated with trastuzumab
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701353/
https://www.ncbi.nlm.nih.gov/pubmed/33263112
http://dx.doi.org/10.1016/j.jaccao.2020.04.010
work_keys_str_mv AT demisseibiniyamg cardiologyinvolvementinpatientswithbreastcancertreatedwithtrastuzumab
AT adusumallisrinath cardiologyinvolvementinpatientswithbreastcancertreatedwithtrastuzumab
AT hubbardrebeccaa cardiologyinvolvementinpatientswithbreastcancertreatedwithtrastuzumab
AT dendulurisrinivas cardiologyinvolvementinpatientswithbreastcancertreatedwithtrastuzumab
AT narayanvivek cardiologyinvolvementinpatientswithbreastcancertreatedwithtrastuzumab
AT clarkamys cardiologyinvolvementinpatientswithbreastcancertreatedwithtrastuzumab
AT shahpayal cardiologyinvolvementinpatientswithbreastcancertreatedwithtrastuzumab
AT knollmanhayley cardiologyinvolvementinpatientswithbreastcancertreatedwithtrastuzumab
AT getzkellyd cardiologyinvolvementinpatientswithbreastcancertreatedwithtrastuzumab
AT aplencrichard cardiologyinvolvementinpatientswithbreastcancertreatedwithtrastuzumab
AT carverjosephr cardiologyinvolvementinpatientswithbreastcancertreatedwithtrastuzumab
AT kybonnie cardiologyinvolvementinpatientswithbreastcancertreatedwithtrastuzumab